|
- Effectiveness Of Vildagliptin Versus Teneligliptin As An Add On Therapy . . .
Vildagliptin has been available for a longer period of time and is more widely studied, Teneligliptin is a newer agent in the class of DPP-4 inhibitors, that has shown comparable safety and efficacy profiles to vildagliptin
- Teneligliptin versus vildagliptin in Indian patients with type 2 . . .
Therefore, the present study was designed to assess the efficacy and safety of vildagliptin and teneligliptin as an add-on therapy to patients inadequately controlled on metformin alone
- Comparative effect of vildagliptin and teneligliptin on HbA1c, glycemic . . .
These studies showed similar efficacy (or better) and safety with teneligliptin as compared to other DPP4Is Teneligliptin also showed additional benefits other than the glycemic control
- Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
The safety profile of teneligliptin is similar to those of other available DPP-4 inhibitors However, caution needs to be exercised when administering teneligliptin to patients who are prone to QT prolongation
- Comparing Vildagliptin SR 100mg and Teneligliptin 20mg in Type 2 . . .
This trial is a Phase IV, Prospective, Randomized, Comparative, Parallel Group, Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Vildagliptin SR 100 mg Versus Teneligliptin 20 mg in Patients with Type 2 Diabetes Mellitus
- What are the considerations for switching from teneligliptin . . .
Teneligliptin may cause QT prolongation —exercise caution in susceptible patients 6 Rare pancreatitis and musculoskeletal side effects reported with DPP-4 inhibitor class 1 Bottom Line Rather than switching from teneligliptin to vildagliptin, reassess your patient's treatment strategy entirely
- Comparative effect of vildagliptin and teneligliptin on HbA1c . . . - IJBCP
The objective of this study is to further investigate the insulin sensitizing properties of Vildagliptin in comparison to those of Teneligliptin Methods: Naive subjects with T2DM were administered 50-100mg day Vildagliptin monotherapy (n = 53)
- Efficacy and safety of teneligliptin versus vildagliptin as add-on to . . .
The present study aimed compared the efficacy and safety profiles of two gliptins, vildagliptin and teneligliptin, in patients with type 2 diabetes as add-on therapy to traditional first-line oral antidiabetic drugs
|
|
|